Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
EyePoint Pharmaceuticals Inc (EYPT)
NASDAQ:EYPT
RESEARCH TOOLSreports
EyePoint Pharmaceuticals (EYPT) Stock Price & Analysis
773 Followers
EYPT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.67 - $30.99
Previous Close$8.8
Volume1.30M
Average Volume (3M)1.17M
Market Cap
$458.34M
Enterprise Value$163.62M
Total Cash (Recent Filing)$299.35M
Total Debt (Recent Filing)$4.62M
Price to Earnings (P/E)―
Beta2.09
Next Earnings
Jul 31, 2024EPS Estimate
-$0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.83
Shares Outstanding52,084,375
10 Day Avg. Volume754,578
30 Day Avg. Volume1,173,907
Standard Deviation0.44
R-Squared0.04
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)1.77
Price to Sales (P/S)9.59
Price to Cash Flow (P/CF)-3.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.11
Enterprise Value/Gross Profit3.56
Enterprise Value/Ebitda-2.10
Forecast
1Y Price Target
$39.50Price Target Upside348.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EyePoint Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Phase 3 study design for Duravyu in wet AMD includes a broader patient population, which could lead to better outcomes and expand commercial opportunities.
Market ValuationThe valuation gap between EYPT and its main competitor is seen as unjustified, leading to a recommendation to buy EYPT shares.
Regulatory ApprovalManagement appears confident in their Phase III program, emphasizing that the program has been fully vetted with the FDA and will include both naive and previously treated patients.
Bears Say
Clinical TrialsThe company reported topline results from the Phase 2 PAVIA trial of DURAVYU in non-proliferative diabetic retinopathy (NPDR), and it did not meet the primary endpoint.
EarningsThis morning EYPT reported 1Q earnings of ($0.55) vs analyst's estimate of ($0.32).
Stock PerformanceEYPT shares fell 43% following the announcement of worse than expected top-line Phase 2 PAVIA study data for EYP-1901/Duravyu in non-proliferative diabetic retinopathy/NPDR.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
EYPT FAQ
What was EyePoint Pharmaceuticals Inc’s price range in the past 12 months?
EyePoint Pharmaceuticals Inc lowest stock price was $5.67 and its highest was $30.99 in the past 12 months.
What is EyePoint Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is EyePoint Pharmaceuticals Inc’s upcoming earnings report date?
EyePoint Pharmaceuticals Inc’s upcoming earnings report date is Jul 31, 2024 which is in 9 days.
How were EyePoint Pharmaceuticals Inc’s earnings last quarter?
EyePoint Pharmaceuticals Inc released its earnings results on May 08, 2024. The company reported -$0.55 earnings per share for the quarter, missing the consensus estimate of -$0.402 by -$0.148.
Is EyePoint Pharmaceuticals Inc overvalued?
According to Wall Street analysts EyePoint Pharmaceuticals Inc’s price is currently Undervalued.
Does EyePoint Pharmaceuticals Inc pay dividends?
EyePoint Pharmaceuticals Inc does not currently pay dividends.
What is EyePoint Pharmaceuticals Inc’s EPS estimate?
EyePoint Pharmaceuticals Inc’s EPS estimate is -$0.54.
How many shares outstanding does EyePoint Pharmaceuticals Inc have?
EyePoint Pharmaceuticals Inc has 52,084,373 shares outstanding.
What happened to EyePoint Pharmaceuticals Inc’s price movement after its last earnings report?
EyePoint Pharmaceuticals Inc reported an EPS of -$0.55 in its last earnings report, missing expectations of -$0.402. Following the earnings report the stock price went down -2.612%.
Which hedge fund is a major shareholder of EyePoint Pharmaceuticals Inc?
Among the largest hedge funds holding EyePoint Pharmaceuticals Inc’s share is RA Capital Management. It holds EyePoint Pharmaceuticals Inc’s shares valued at 19M.
---
EyePoint Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.50 (348.86% Upside)
$39.50 (348.86% Upside)
Blogger Sentiment
Bullish
EYPT Sentiment 75%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $20.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.48%
12-Months-Change
Fundamentals
Return on Equity
-48.07%
Trailing 12-Months
Asset Growth
112.98%
Trailing 12-Months
Company Description
EyePoint Pharmaceuticals Inc
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercializing of ophthalmic products. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.
---
EYPT Earnings Call
Q4 2024
0:00 / 0:00
---
EYPT Stock 12 Month Forecast
Average Price Target
$39.50
▲(348.86% Upside)
Technical Analysis
Best Analysts Covering EYPT
1 Year
1 Year Success Rate
5/10 ratings generated profit
1 Year Average Return
+20.10%
reiterated a buy rating 26 days ago
Copying Colleen M. Kusy's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +20.10% per trade.
---